Pharmacokinetics and Metabolism Study in Healthy Male Participants

Bristol-Myers Squibb (BMS)

Status and phase: Completed; Phase 1

Conditions: Cancer

Treatments: Drug: BMS-986205

Study type: Interventional

Funder types: Industry

Identifiers

NCT03247283

CA017-052A

Details and patient eligibility

About

Phase 1 Phamacokinetic and metabolism study of BMS-986205 in healthy males

Enrollment: 9 patients

Sex: Male

Ages: 18 to 50 years old

Volunteers: Accepts Healthy Volunteers

Inclusion criteria

• Body weight 75-95kg, BMI 18.0-32.0 kg/m^2
• Refrain from sperm donation 110 days after dosing

Exclusion criteria

• Current or recent gastrointestinal disease
• Any GI surgery that could impact drug absorption
• Active, known, or suspected autoimmune disease

Other protocol defined inclusion/exclusion criteria could apply

Trial design

Primary purpose: Health Services Research

Allocation: N/A

Interventional model: Single Group Assignment

Masking: None (Open label)

---

9 participants in 1 patient group

Single Oral Dose of BMS-986205

Experimental group

Treatment:

Drug: BMS-986205